John Markels - Net Worth and Insider Trading

John Markels Net Worth

The estimated net worth of John Markels is at least $35,732 dollars as of 2024-03-03. John Markels is the Director of Sangamo Therapeutics Inc and owns about 32,484 shares of Sangamo Therapeutics Inc (SGMO) stock worth over $35,732. Details can be seen in John Markels's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John Markels has not made any transactions after 2022-06-03 and currently still holds the listed stock(s).

Transaction Summary of John Markels


John Markels Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Markels owns 2 companies in total, including Sangamo Therapeutics Inc () , and Arcturus Therapeutics Holdings Inc () .

Click here to see the complete history of John Markels’s form 4 insider trades.

Insider Ownership Summary of John Markels

Ticker Comapny Transaction Date Type of Owner
Sangamo Therapeutics Inc 2022-06-03 director
Arcturus Therapeutics Holdings Inc 2022-12-08 director

John Markels Latest Holdings Summary

John Markels currently owns a total of 1 stock. John Markels owns 32,484 shares of Sangamo Therapeutics Inc (SGMO) as of June 3, 2022, with a value of $35,732.

Latest Holdings of John Markels

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SGMO Sangamo Therapeutics Inc 2022-06-03 32,484 1.10 35,732

Holding Weightings of John Markels

John Markels Form 4 Trading Tracker

According to the SEC Form 4 filings, John Markels has made a total of 1 transactions in Sangamo Therapeutics Inc (SGMO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Sangamo Therapeutics Inc is the acquisition of 6,784 shares on June 3, 2022, which cost John Markels around $25,033.

Insider Trading History of John Markels

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John Markels Trading Performance

GuruFocus tracks the stock performance after each of John Markels's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Markels is 48.66%. GuruFocus also compares John Markels's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Markels within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John Markels's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John Markels

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 15.05 48.66 -1.88 -69.09
Relative Return to S&P 500(%) 21.94 53.15 -0.98 -73.32

John Markels Ownership Network

Ownership Network List of John Markels

No Data

Ownership Network Relation of John Markels

John Markels Owned Company Details

What does Sangamo Therapeutics Inc do?

Who are the key executives at Sangamo Therapeutics Inc?

John Markels is the director of Sangamo Therapeutics Inc. Other key executives at Sangamo Therapeutics Inc include 10 percent owner Biogen Inc. , SVP-Chief Development Officer Nathalie Dubois-stringfellow , and 10 percent owner Biogen Ma Inc. .

Sangamo Therapeutics Inc () Insider Trades Summary

Over the past 18 months, John Markels made no insider transaction in Sangamo Therapeutics Inc (). Other recent insider transactions involving Sangamo Therapeutics Inc () include a net sale of 6,000,000 shares made by Biogen Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Sangamo Therapeutics Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,000,000 shares of Sangamo Therapeutics Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,000,000 shares.

Sangamo Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.


Sangamo Therapeutics Inc Insider Transactions

No Available Data

John Markels Mailing Address

Above is the net worth, insider trading, and ownership report for John Markels. You might contact John Markels via mailing address: C/o Sangamo Therapeutics, Inc., Point Richmond Tech Ctr, 501 Canal Blvd., Richmond Ca 94804.

Discussions on John Markels

No discussions yet.